Results
As shown in Figs 1 and 2 there was a clear decrease both in serum cholesterol and triglyceride values after treatment with 800 mg of gemfibrozil daily. The mean cholesterol level after four months of treatment fell from 11.1 mmol/l to 7.54 mmol/l and that of the triglycerides from 4.08 mmol/l to 1.36 mmol/l. Table 1 shows the simultaneous changes in serum lipoprotein concentrations where a definite decrease both in beta and pre-beta fractions can be seen. The concentration of the alpha-fraction, by contrast, was increased.
There were no adverse reactions as judged from GPT, CK or hematology measurements. In 1 subject, serum lactate dehydrogenase (LD) showed a slight transient increase above the normal level. Total serum protein concentration remained constant. The weights of the patients were also unchanged during the trial.
Discussion
Lipoprotein profiles in the nephrotic syndrome have been studied by Chopra et al. (1971) and Newmark et al. (1975) . Types Ila, Ilb and V were found to be common in the nephrotic syndrome, while type IV, common for urmmic subjects (Brons et al. 1972) , is distinctly uncommon. In the present series all subjects had elevated levels of both beta and pre-beta lipoproteins and this fits with the previous observations on patients with the nephrotic syndrome. Treatment with gemfibrozil decreased both these lipoprotein fractions. The beta-fraction decreased by 27% and the pre-beta by 67%. All initially elevated pre- Hyperlipidcemia is a common finding in the nephrotic syndrome. Its pathogenesis is elusive. Hypoalbuminemia seems to be an important factor, and infusion of albumin in nephrotic patients is known to decrease plasma lipid concentrations (Baxter et al. 1961) . Marsh & Drabkin (1960) have concluded from animal experiments that hepatic synthesis of lipoproteins is increased in nephrotics. Changes in lipoprotein lipase activity may also contribute to the hyperlipidemia of the nephrotic syndrome (Hyman et al. 1969 , Yamada & Matsuda 1970 .
A variety of diseases may damage the glomeruli to the extent that profuse proteinuria and eventually the nephrotic syndrome result. In most cases the prognosis of the individual patient depends on the progress of the primary disease. If nephrotic subjects have an increased risk of myocardial infarction and accelerated atherosclerosis (Berlyne & Mallick 1969 ) treatment of the hyperlipidemia may deserve consideration in those having a restricted primary lesion.
The purpose of the present study was to investigate the efficacy and tolerance of gemfibrozil in patients with the nephrotic syndrome.
Patients and Methods
Five nephrotic patients, aged 26 to 67 years, volunteered for the trial. Three had secondary amyloidosis and 2 suffered from glomerulonephritis. Two were males and 3 females. The (Miller & Miller 1975 , Berg et al. 1976 ) elevation of the alpha-fraction by gemfibrozil treatment may be of importance. In both urxmic (Pierides et al. 1975 ) and nonurnmic patients with the nephrotic syndrome (Pridgman et al. 1972) clofibrate is known to lead to muscle weakness and tenderness, together with a rise in serum creatine kinase. No such findings were seen in the present series using gemfibrozil.
A slight transient elevation in serum LD was observed in one subject only.
It is concluded that gemfibrozil appears to be effective and safe for the treatment of hyperlipidmmias associated with the nephrotic syndrome. However, its precise mechanism of action in this condition remains to be resolved.
